Arden Trust’s 10x Genomics TXG Stock Holding History

Arden Trust’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,056	Closed	-$308K	–	292
2022 Q1	$308K	Buy	4,056 +1,047	+35%	+$91.6K	0.06%	226
2021 Q4	$449K	Buy	+3,009	New	+$461K	0.08%	214

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Arden Trust's TXG Position: Q2 2022 in Review

Arden Trust sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 4,056 shares — an estimated $308K sold.

Arden Trust first reported a position in TXG in Q4 2021 and held it in 2 quarters. The position peaked at $449K in Q4 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Arden Trust reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Arden Trust sold 4,056 10x Genomics shares in Q2 2022, an estimated $308K.
Arden Trust first reported a position in 10x Genomics in Q4 2021 and held it in 2 quarters.
Arden Trust's 10x Genomics position peaked at $449K in Q4 2021.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Arden Trust's 13F filing for Q2 2022, filed 12 Jul 2022.